GT Biopharma Inc (GTBP NASDAQ) stock market data APIs
$0.8185
-0.02(-2.4%)
as of September 18, 2025
Try our APIs with
free plan!
GT Biopharma Inc Financial Data Overview
Price chart is built with
Anychart
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms. It develops GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550 that targets B7-H3 on the surface of advanced solid tumors; and GTB-7550, a product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.
Prev. Close
0.8185
Open
0.7964
High
0.8368
Low
0.7841
52 wk Range
0.63-4.1
Market Cap
2 808 K
Shares Outstanding
3 558 K
EPS
-0.55
Beta
1.366
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get GT Biopharma Inc data using free add-ons & libraries
Get GT Biopharma Inc Fundamental Data
GT Biopharma Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -6 760 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-14
- EPS/Forecast: -0.68
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
GT Biopharma Inc News
New
Friday's after hours session: top gainers and losers
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. [postmarket] TODAY'S AFTER HOURS GAINERS TICKER CHANGE COMMENT GTBP [http...
GT Biopharma Reports Second Quarter 2025 Financial Results
GTB-3650 TriKE® Phase 1 trial has successfully completed Cohort 1 and Cohort 2 dosing, treating a total of four patients; following Cohort 2’s formal safety review, it has advanced into Cohort 3 an...
GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2
The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful safety review of Cohort 2 with no safety or tolerability issues observed...
GT Biopharma Appoints New Member to its Board of Directors
SAN FRANCISCO, CALIFORNIA, June 13, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeu...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
